Although molecular classification of endometrial cancer utilizing POLE mutation testing has been developed and widely studied in the TCGA, Vancouver, and Leiden classifications, such molecular analysis still has limitations, namely in that POLE mutation testing is too expensive to be carried out in daily routine practice. The gene discussed is POLE; the disease is endometrial cancer.